ReviewDiabetic medicine : a journal of the British Diabetic Association2011
Thiazolidinediones and fracture risk in patients with Type 2 diabetes.
Review in Diabetic medicine : a journal of the British Diabetic Association, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02491333 (The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial
Who cites it
31 citing papers in PubMed, 78 citations in OpenAlex.
- Trial
- Bone Marker Proteins at Baseline and After Insulin-Induced Hypoglycaemia in Type 2 Diabetes.International journal of molecular sciences · 2025Article
- White adipose tissue browning and peroxisome proliferator activated receptors in MASLD.Frontiers in endocrinology · 2025Review
- Early Prediction Model for Osteoporotic Fracture in Type 2 Diabetes Patients: A Nomogram Approach Based on a Single-Center Retrospective Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Cladosporols and PPARγ: Same Gun, Same Bullet, More Targets.Biomolecules · 2024Review
- Glucagon-like Peptide-1 Receptor Agonists and Diabetic Osteopathy: Another Positive Effect of Incretines? A 12 Months Longitudinal Study.Calcified tissue international · 2024Article
- Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis.World journal of diabetes · 2023Article
- Romosozumab and cardiovascular safety-should we learn lessons from pioglitazone?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022Article
- Adipose tissue in health and disease.Open biology · 2020Review
- Herbal Decoction Divya-Peedantak-Kwath Alleviates Allodynia and Hyperalgesia in Mice Model of Chemotherapy-Induced Peripheral Neuropathy via Modulation in Cytokine Response.Frontiers in pharmacology · 2020Article
- Diabetes pharmacotherapy and effects on the musculoskeletal system.Diabetes/metabolism research and reviews · 2019Review
- Bronchopulmonary Dysplasia: Crosstalk Between PPARγ, WNT/β-Catenin and TGF-β Pathways; The Potential Therapeutic Role of PPARγ Agonists.Frontiers in pediatrics · 2019Review
- Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.British journal of clinical pharmacology · 2018Article
- The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF-Journal of immunology research · 2018Article
- PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma.Nuclear receptor research · 2018Article
- Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs.Calcified tissue international · 2015Article
- Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Review
- Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.Calcified tissue international · 2015Article
- Sulfonylurea use and risk of hip fractures among elderly men and women with type 2 diabetes.Drugs & aging · 2015Article
- Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.Advances in therapy · 2014Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thiazolidinediones are widely used effective drugs for the management of hyperglycaemia in Type 2 diabetes and may provide additional metabolic benefits. Any advantages of these agents need to be considered in the context of any potential risk from adverse events. Recent evidence from several sources, including large-scale randomized controlled trials and observational studies, suggests that long-term use of thiazolidinediones is associated with bone loss and an increased risk of fractures in women with Type 2 diabetes. As patients with Type 2 diabetes are already at high risk for fractures, the clinical relevance of this reported association with thiazolidinedione therapy deserves careful consideration. Generally, the fracture risk with thiazolidinediones appears similar in magnitude to that associated with several other widely used drug classes, although there are unanswered questions regarding susceptibility factors, differential effects on bone sites and potential management approaches. This article provides a comprehensive overview of the evidence for an increase in fracture risk with thiazolidinediones and places it in the context of recent analyses of fracture risk with other commonly used drug classes. The potential clinical implications of any association are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.